Long-Term GAD-alum Treatment Effect on Different T-Cell Subpopulations in Healthy Children Positive for Multiple Beta Cell Autoantibodies

Figure 4

Cross-sectional analysis of (a) GADA titers and (b) ZNT8WA titers stratified by treatment (GAD65-alum (Diamyd)/placebo) presented as boxplots at study follow-up visits 0, 1, 2, 4, 6, 8, and 10. (a) GADA titers were higher in the GAD65-alum-treated group compared to placebo at visits 4 and 6. (b) ZnT8WA titers were higher in in the GAD65-alum-treated group compared to placebo at visits 4, 6, and 8. The estimates, 95% confidence intervals, and values for those visits are provided in the figure.

(a)

(b)